Download PDF
Thromb Haemost 1982; 48(01): 076-077
DOI: 10.1055/s-0038-1657220
Original Article
Schattauer GmbH Stuttgart

Factor IX Thrombogenicity: In Vivo Effects on Coagulation Activation and a Case Report of Disseminated Intravascular Coagulation

M Small
The University Department of Medicine, Royal Infirmary, Glasgow, U. K.
,
G D O Lowe
The University Department of Medicine, Royal Infirmary, Glasgow, U. K.
,
J T Douglas
The University Department of Medicine, Royal Infirmary, Glasgow, U. K.
,
C D Forbes
The University Department of Medicine, Royal Infirmary, Glasgow, U. K.
,
C R M Prentice
The University Department of Medicine, Royal Infirmary, Glasgow, U. K.
› Author Affiliations
Further Information

Publication History

Received 25 January 1982

Accepted 03 June 1982

Publication Date:
13 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

An episode of defibrination with bleeding following high dose Edinburgh Factor IX (D.E.F.IX) replacement in a patient with haemophilia B undergoing knee joint replacement is reported. We have also monitored plasma fibrinopeptide A levels in patients with haemophilia B following ten standard doses of D.E.F.IX (15–20 u/kg) and have been unable to document any change. Activation of the coagulation system, as previously noted, appears to be related to the use of Factor IX concentrates in high doses.

Keywords

Factor IX concentrates - Fibrinopeptide A levels - Disseminated intravascular coagulation
 

  • References

  • 1 Prowse CV, Cash JD. The use of Factor IX concentrates in man: a nine year experience, of Scottish Concentrates in the South-East of Scotland. Br J Haematol 1981; 47: 91-104
    CrossrefPubMedGoogle Scholar
  • 2 Lane JL, Rizza CR, Snape TJ. A five year experience of the use of factor IX Type DE (1) Concentrate for the treatment of Christmas disease at Oxford. Br J Haematol 1975; 30: 435-446
    CrossrefPubMedGoogle Scholar
  • 3 Chandra S, Wickerhauser M. Large scale preparation of non-thrombogenic prothrombin complex. Thromb Res 1978; 12: 571-582
    CrossrefPubMedGoogle Scholar
  • 4 White GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159-170
    PubMedGoogle Scholar
  • 5 Hultin MB. Activated clotting factors in Factor IX Concentrates. Blood 1979; 54: 1028-1038
    PubMedGoogle Scholar
  • 6 Middleton SM, Bennett JH, Smith JK. A therapeutic concentrate of coagulation factors II, IX and X from citrated factor-VIII depleted plasma. Vox Sang 1973; 24: 441-456
    PubMedGoogle Scholar
  • 7 Kasper CK. Thromboembolic complications. Thromb Haemostas 1975; 33: 640-644
    PubMedGoogle Scholar
  • 8 Cederbaum AI, Blatt PM, Roberts HR. Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med 1976; 84: 683-687
    CrossrefPubMedGoogle Scholar
  • 9 Machin SJ, Miller BR. Thrombosis and factor IX concentrates (Letter). Lancet 1978; 1: 1367
    PubMedGoogle Scholar
  • 10 Vigano S, Cattaneo M, Gervasori W, Manucci PM. Increased fibrinopeptide A after prothrombin complex concentrates. Thromb Haemostas 1980; 44: 72-75
    PubMedGoogle Scholar
  • 11 Prager D, Djerassi I, Eyster E, Gill FM, Kajani NK, Lewis JH, Lusch C, Rice S, Shapiro SS. Pennsylvania state-wide Haemophilia Program: Summary of Immediate Reactions with the use of Factor VIII and Factor IX Concentrate. Blood 1979; 53: 1012-1013
    PubMedGoogle Scholar